# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stereotaxis (NYSE:STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, tod...
Stereotaxis (AMEX:STXS) reported quarterly losses of $(0.06) per share which met the analyst consensus estimate. This is a 14.2...
Lake Street analyst Frank Takkinen maintains Stereotaxis (AMEX:STXS) with a Buy and raises the price target from $3 to $4.
Roth MKM analyst Jason Wittes reiterates Stereotaxis (AMEX:STXS) with a Buy and maintains $5 price target.